Global Drug based on CAR T-Cell Production, Demand and Key Producers, 2022-2028
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
This report studies the global Drug based on CAR T-Cell demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Drug based on CAR T-Cell, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Drug based on CAR T-Cell that contribute to its increasing demand across many markets.
The global Drug based on CAR T-Cell market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Drug based on CAR T-Cell total market, 2017-2028, (USD Million)
Global Drug based on CAR T-Cell total market by region & country, CAGR, 2017-2028, (USD Million)
U.S. VS China: Drug based on CAR T-Cell total market, key domestic companies and share, (USD Million)
Global Drug based on CAR T-Cell revenue by player and market share 2017-2022, (USD Million)
Global Drug based on CAR T-Cell total market by Type, CAGR, 2017-2028, (USD Million)
Global Drug based on CAR T-Cell total market by Application, CAGR, 2017-2028, (USD Million)
This reports profiles major players in the global Drug based on CAR T-Cell market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Drug based on CAR T-Cell market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Drug based on CAR T-Cell Market, By Region:
1. How big is the global Drug based on CAR T-Cell market?
2. What is the demand of the global Drug based on CAR T-Cell market?
3. What is the year over year growth of the global Drug based on CAR T-Cell market?
4. What is the total value of the global Drug based on CAR T-Cell market?
5. Who are the major players in the global Drug based on CAR T-Cell market?
6. What are the growth factors driving the market demand?
This report studies the global Drug based on CAR T-Cell demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Drug based on CAR T-Cell, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Drug based on CAR T-Cell that contribute to its increasing demand across many markets.
The global Drug based on CAR T-Cell market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).
Highlights and key features of the study
Global Drug based on CAR T-Cell total market, 2017-2028, (USD Million)
Global Drug based on CAR T-Cell total market by region & country, CAGR, 2017-2028, (USD Million)
U.S. VS China: Drug based on CAR T-Cell total market, key domestic companies and share, (USD Million)
Global Drug based on CAR T-Cell revenue by player and market share 2017-2022, (USD Million)
Global Drug based on CAR T-Cell total market by Type, CAGR, 2017-2028, (USD Million)
Global Drug based on CAR T-Cell total market by Application, CAGR, 2017-2028, (USD Million)
This reports profiles major players in the global Drug based on CAR T-Cell market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Drug based on CAR T-Cell market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.
Global Drug based on CAR T-Cell Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- CD19-targeted
- BCMA-targeted
- Lymphoma
- Multiple Myeloma
- Novartis
- Gilead Sciences
- Bristol-Myers Squibb
- J & J
- JW Therapeutics
- FOSUNKite
- CARsgen Therapeutics (Pipeline)
- CARsgen Therapeutics
- Autolus Therapeutics
- Sorrento Therapeutics
- Mustang Bio
- Bluebird Bio
- Cellectis
- Allogene Therapeutics
- Celyad
1. How big is the global Drug based on CAR T-Cell market?
2. What is the demand of the global Drug based on CAR T-Cell market?
3. What is the year over year growth of the global Drug based on CAR T-Cell market?
4. What is the total value of the global Drug based on CAR T-Cell market?
5. Who are the major players in the global Drug based on CAR T-Cell market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Drug based on CAR T-Cell Introduction
1.2 World Drug based on CAR T-Cell Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Drug based on CAR T-Cell Total Market by Region
1.3.1 World Drug based on CAR T-Cell Market Size by Region (2017-2028)
1.3.2 United States Drug based on CAR T-Cell Market Size (2017-2028)
1.3.3 China Drug based on CAR T-Cell Market Size (2017-2028)
1.3.4 Europe Drug based on CAR T-Cell Market Size (2017-2028)
1.3.5 Japan Drug based on CAR T-Cell Market Size (2017-2028)
1.3.6 South Korea Drug based on CAR T-Cell Market Size (2017-2028)
1.3.7 ASEAN Drug based on CAR T-Cell Market Size (2017-2028)
1.3.8 India Drug based on CAR T-Cell Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Drug based on CAR T-Cell Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Drug based on CAR T-Cell Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 WORLD DRUG BASED ON CAR T-CELL COMPANIES COMPETITIVE ANALYSIS
2.1 World Drug based on CAR T-Cell Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
2.2.1 Global Drug based on CAR T-Cell Industry Rank of Major Players
2.2.2 Global Concentration Ratios (CR4) for Drug based on CAR T-Cell in 2021
2.2.3 Global Concentration Ratios (CR8) for Drug based on CAR T-Cell in 2021
2.3 Drug based on CAR T-Cell Company Evaluation Quadrant
2.4 Drug based on CAR T-Cell Market: Overall Company Footprint Analysis
2.4.1 Drug based on CAR T-Cell Market: Region Footprint
2.4.2 Drug based on CAR T-Cell Market: Company Product Type Footprint
2.4.3 Drug based on CAR T-Cell Market: Company Product Application Footprint
2.5 Competitive Environment
2.5.1 Historical Structure of the Industry
2.5.2 Barriers of Market Entry
2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity
3 UNITED STATES VS CHINA VS REST OF THE WORLD
3.1 United States VS China: Drug based on CAR T-Cell Market Comparison
3.1.1 United States VS China: Drug based on CAR T-Cell Market Size Comparison (2017 & 2021 & 2028)
3.1.2 United States VS China: Drug based on CAR T-Cell Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Drug based on CAR T-Cell Major Players and Market Share, 2017-2022
3.2.1 Major Players of Drug based on CAR T-Cell in United States, Headquarters (States, Country)
3.2.2 United States Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022)
3.3 China Drug based on CAR T-Cell Major Players and Market Share, 2017-2022
3.3.1 Major Players of Drug based on CAR T-Cell in China, Headquarters (Province, Country)
3.3.2 China Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Drug based on CAR T-Cell Major Players and Market Share, 2017-2022
3.4.1 Major Players of Drug based on CAR T-Cell in Rest of World, Headquarters (State, Country)
3.4.2 Rest of World Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022)
4 MARKET ANALYSIS BY TYPE
4.1 World Drug based on CAR T-Cell Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
4.2.1 CD19-targeted
4.2.2 BCMA-targeted
4.3 Market Segment by Type
4.3.1 World Drug based on CAR T-Cell Market Size by Type (2017-2022)
4.3.2 World Drug based on CAR T-Cell Market Size by Type (2023-2028)
4.3.3 World Drug based on CAR T-Cell Market Size Market Share by Type (2017-2028)
5 MARKET ANALYSIS BY APPLICATION
5.1 World Drug based on CAR T-Cell Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
5.2.1 Lymphoma
5.2.2 Multiple Myeloma
5.3 Market Segment by Application
5.3.1 World Drug based on CAR T-Cell Market Size by Application (2017-2022)
5.3.2 World Drug based on CAR T-Cell Market Size by Application (2023-2028)
5.3.3 World Drug based on CAR T-Cell Market Size by Application (2017-2028)
6 COMPANY PROFILES
6.1 Novartis
6.1.1 Novartis Details
6.1.2 Novartis Major Business
6.1.3 Novartis Drug based on CAR T-Cell Product and Services
6.1.4 Novartis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.1.5 Novartis Recent Developments/Updates
6.1.6 Novartis Competitive Strengths & Weaknesses
6.2 Gilead Sciences
6.2.1 Gilead Sciences Details
6.2.2 Gilead Sciences Major Business
6.2.3 Gilead Sciences Drug based on CAR T-Cell Product and Services
6.2.4 Gilead Sciences Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.2.5 Gilead Sciences Recent Developments/Updates
6.2.6 Gilead Sciences Competitive Strengths & Weaknesses
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Details
6.3.2 Bristol-Myers Squibb Major Business
6.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Product and Services
6.3.4 Bristol-Myers Squibb Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.3.5 Bristol-Myers Squibb Recent Developments/Updates
6.3.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
6.4 J & J
6.4.1 J & J Details
6.4.2 J & J Major Business
6.4.3 J & J Drug based on CAR T-Cell Product and Services
6.4.4 J & J Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.4.5 J & J Recent Developments/Updates
6.4.6 J & J Competitive Strengths & Weaknesses
6.5 JW Therapeutics
6.5.1 JW Therapeutics Details
6.5.2 JW Therapeutics Major Business
6.5.3 JW Therapeutics Drug based on CAR T-Cell Product and Services
6.5.4 JW Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.5.5 JW Therapeutics Recent Developments/Updates
6.5.6 JW Therapeutics Competitive Strengths & Weaknesses
6.6 FOSUNKite
6.6.1 FOSUNKite Details
6.6.2 FOSUNKite Major Business
6.6.3 FOSUNKite Drug based on CAR T-Cell Product and Services
6.6.4 FOSUNKite Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.6.5 FOSUNKite Recent Developments/Updates
6.6.6 FOSUNKite Competitive Strengths & Weaknesses
6.7 CARsgen Therapeutics (Pipeline)
6.7.1 CARsgen Therapeutics (Pipeline) Details
6.7.2 CARsgen Therapeutics (Pipeline) Major Business
6.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product and Services
6.7.4 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.7.5 CARsgen Therapeutics (Pipeline) Recent Developments/Updates
6.7.6 CARsgen Therapeutics (Pipeline) Competitive Strengths & Weaknesses
6.8 CARsgen Therapeutics
6.8.1 CARsgen Therapeutics Details
6.8.2 CARsgen Therapeutics Major Business
6.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Product and Services
6.8.4 CARsgen Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.8.5 CARsgen Therapeutics Recent Developments/Updates
6.8.6 CARsgen Therapeutics Competitive Strengths & Weaknesses
6.9 Autolus Therapeutics
6.9.1 Autolus Therapeutics Details
6.9.2 Autolus Therapeutics Major Business
6.9.3 Autolus Therapeutics Drug based on CAR T-Cell Product and Services
6.9.4 Autolus Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.9.5 Autolus Therapeutics Recent Developments/Updates
6.9.6 Autolus Therapeutics Competitive Strengths & Weaknesses
6.10 Sorrento Therapeutics
6.10.1 Sorrento Therapeutics Details
6.10.2 Sorrento Therapeutics Major Business
6.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Product and Services
6.10.4 Sorrento Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.10.5 Sorrento Therapeutics Recent Developments/Updates
6.10.6 Sorrento Therapeutics Competitive Strengths & Weaknesses
6.11 Mustang Bio
6.11.1 Mustang Bio Details
6.11.2 Mustang Bio Major Business
6.11.3 Mustang Bio Drug based on CAR T-Cell Product and Services
6.11.4 Mustang Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.11.5 Mustang Bio Recent Developments/Updates
6.11.6 Mustang Bio Competitive Strengths & Weaknesses
6.12 Bluebird Bio
6.12.1 Bluebird Bio Details
6.12.2 Bluebird Bio Major Business
6.12.3 Bluebird Bio Drug based on CAR T-Cell Product and Services
6.12.4 Bluebird Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.12.5 Bluebird Bio Recent Developments/Updates
6.12.6 Bluebird Bio Competitive Strengths & Weaknesses
6.13 Cellectis
6.13.1 Cellectis Details
6.13.2 Cellectis Major Business
6.13.3 Cellectis Drug based on CAR T-Cell Product and Services
6.13.4 Cellectis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.13.5 Cellectis Recent Developments/Updates
6.13.6 Cellectis Competitive Strengths & Weaknesses
6.14 Allogene Therapeutics
6.14.1 Allogene Therapeutics Details
6.14.2 Allogene Therapeutics Major Business
6.14.3 Allogene Therapeutics Drug based on CAR T-Cell Product and Services
6.14.4 Allogene Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.14.5 Allogene Therapeutics Recent Developments/Updates
6.14.6 Allogene Therapeutics Competitive Strengths & Weaknesses
6.15 Celyad
6.15.1 Celyad Details
6.15.2 Celyad Major Business
6.15.3 Celyad Drug based on CAR T-Cell Product and Services
6.15.4 Celyad Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.15.5 Celyad Recent Developments/Updates
6.15.6 Celyad Competitive Strengths & Weaknesses
7 RAW MATERIAL AND INDUSTRY CHAIN
7.1 Raw Material of Drug based on CAR T-Cell and Key Manufacturers
7.2 Drug based on CAR T-Cell Manufacturing Costs
7.3 Drug based on CAR T-Cell Production Process
7.4 Drug based on CAR T-Cell Industrial Chain
8 DISTRIBUTION CHANNEL ANALYSIS
8.1 Distribution Channel Breakdown for Drug based on CAR T-Cell Shipments (%): 2017-2028
8.1.1 Direct Channel
8.1.2 Indirect Channel
8.2 Drug based on CAR T-Cell Typical Distributors
8.3 Drug based on CAR T-Cell Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Drug based on CAR T-Cell Introduction
1.2 World Drug based on CAR T-Cell Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Drug based on CAR T-Cell Total Market by Region
1.3.1 World Drug based on CAR T-Cell Market Size by Region (2017-2028)
1.3.2 United States Drug based on CAR T-Cell Market Size (2017-2028)
1.3.3 China Drug based on CAR T-Cell Market Size (2017-2028)
1.3.4 Europe Drug based on CAR T-Cell Market Size (2017-2028)
1.3.5 Japan Drug based on CAR T-Cell Market Size (2017-2028)
1.3.6 South Korea Drug based on CAR T-Cell Market Size (2017-2028)
1.3.7 ASEAN Drug based on CAR T-Cell Market Size (2017-2028)
1.3.8 India Drug based on CAR T-Cell Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
1.4.1 Drug based on CAR T-Cell Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Drug based on CAR T-Cell Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 WORLD DRUG BASED ON CAR T-CELL COMPANIES COMPETITIVE ANALYSIS
2.1 World Drug based on CAR T-Cell Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
2.2.1 Global Drug based on CAR T-Cell Industry Rank of Major Players
2.2.2 Global Concentration Ratios (CR4) for Drug based on CAR T-Cell in 2021
2.2.3 Global Concentration Ratios (CR8) for Drug based on CAR T-Cell in 2021
2.3 Drug based on CAR T-Cell Company Evaluation Quadrant
2.4 Drug based on CAR T-Cell Market: Overall Company Footprint Analysis
2.4.1 Drug based on CAR T-Cell Market: Region Footprint
2.4.2 Drug based on CAR T-Cell Market: Company Product Type Footprint
2.4.3 Drug based on CAR T-Cell Market: Company Product Application Footprint
2.5 Competitive Environment
2.5.1 Historical Structure of the Industry
2.5.2 Barriers of Market Entry
2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity
3 UNITED STATES VS CHINA VS REST OF THE WORLD
3.1 United States VS China: Drug based on CAR T-Cell Market Comparison
3.1.1 United States VS China: Drug based on CAR T-Cell Market Size Comparison (2017 & 2021 & 2028)
3.1.2 United States VS China: Drug based on CAR T-Cell Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Drug based on CAR T-Cell Major Players and Market Share, 2017-2022
3.2.1 Major Players of Drug based on CAR T-Cell in United States, Headquarters (States, Country)
3.2.2 United States Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022)
3.3 China Drug based on CAR T-Cell Major Players and Market Share, 2017-2022
3.3.1 Major Players of Drug based on CAR T-Cell in China, Headquarters (Province, Country)
3.3.2 China Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Drug based on CAR T-Cell Major Players and Market Share, 2017-2022
3.4.1 Major Players of Drug based on CAR T-Cell in Rest of World, Headquarters (State, Country)
3.4.2 Rest of World Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022)
4 MARKET ANALYSIS BY TYPE
4.1 World Drug based on CAR T-Cell Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
4.2.1 CD19-targeted
4.2.2 BCMA-targeted
4.3 Market Segment by Type
4.3.1 World Drug based on CAR T-Cell Market Size by Type (2017-2022)
4.3.2 World Drug based on CAR T-Cell Market Size by Type (2023-2028)
4.3.3 World Drug based on CAR T-Cell Market Size Market Share by Type (2017-2028)
5 MARKET ANALYSIS BY APPLICATION
5.1 World Drug based on CAR T-Cell Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
5.2.1 Lymphoma
5.2.2 Multiple Myeloma
5.3 Market Segment by Application
5.3.1 World Drug based on CAR T-Cell Market Size by Application (2017-2022)
5.3.2 World Drug based on CAR T-Cell Market Size by Application (2023-2028)
5.3.3 World Drug based on CAR T-Cell Market Size by Application (2017-2028)
6 COMPANY PROFILES
6.1 Novartis
6.1.1 Novartis Details
6.1.2 Novartis Major Business
6.1.3 Novartis Drug based on CAR T-Cell Product and Services
6.1.4 Novartis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.1.5 Novartis Recent Developments/Updates
6.1.6 Novartis Competitive Strengths & Weaknesses
6.2 Gilead Sciences
6.2.1 Gilead Sciences Details
6.2.2 Gilead Sciences Major Business
6.2.3 Gilead Sciences Drug based on CAR T-Cell Product and Services
6.2.4 Gilead Sciences Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.2.5 Gilead Sciences Recent Developments/Updates
6.2.6 Gilead Sciences Competitive Strengths & Weaknesses
6.3 Bristol-Myers Squibb
6.3.1 Bristol-Myers Squibb Details
6.3.2 Bristol-Myers Squibb Major Business
6.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Product and Services
6.3.4 Bristol-Myers Squibb Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.3.5 Bristol-Myers Squibb Recent Developments/Updates
6.3.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
6.4 J & J
6.4.1 J & J Details
6.4.2 J & J Major Business
6.4.3 J & J Drug based on CAR T-Cell Product and Services
6.4.4 J & J Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.4.5 J & J Recent Developments/Updates
6.4.6 J & J Competitive Strengths & Weaknesses
6.5 JW Therapeutics
6.5.1 JW Therapeutics Details
6.5.2 JW Therapeutics Major Business
6.5.3 JW Therapeutics Drug based on CAR T-Cell Product and Services
6.5.4 JW Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.5.5 JW Therapeutics Recent Developments/Updates
6.5.6 JW Therapeutics Competitive Strengths & Weaknesses
6.6 FOSUNKite
6.6.1 FOSUNKite Details
6.6.2 FOSUNKite Major Business
6.6.3 FOSUNKite Drug based on CAR T-Cell Product and Services
6.6.4 FOSUNKite Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.6.5 FOSUNKite Recent Developments/Updates
6.6.6 FOSUNKite Competitive Strengths & Weaknesses
6.7 CARsgen Therapeutics (Pipeline)
6.7.1 CARsgen Therapeutics (Pipeline) Details
6.7.2 CARsgen Therapeutics (Pipeline) Major Business
6.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product and Services
6.7.4 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.7.5 CARsgen Therapeutics (Pipeline) Recent Developments/Updates
6.7.6 CARsgen Therapeutics (Pipeline) Competitive Strengths & Weaknesses
6.8 CARsgen Therapeutics
6.8.1 CARsgen Therapeutics Details
6.8.2 CARsgen Therapeutics Major Business
6.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Product and Services
6.8.4 CARsgen Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.8.5 CARsgen Therapeutics Recent Developments/Updates
6.8.6 CARsgen Therapeutics Competitive Strengths & Weaknesses
6.9 Autolus Therapeutics
6.9.1 Autolus Therapeutics Details
6.9.2 Autolus Therapeutics Major Business
6.9.3 Autolus Therapeutics Drug based on CAR T-Cell Product and Services
6.9.4 Autolus Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.9.5 Autolus Therapeutics Recent Developments/Updates
6.9.6 Autolus Therapeutics Competitive Strengths & Weaknesses
6.10 Sorrento Therapeutics
6.10.1 Sorrento Therapeutics Details
6.10.2 Sorrento Therapeutics Major Business
6.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Product and Services
6.10.4 Sorrento Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.10.5 Sorrento Therapeutics Recent Developments/Updates
6.10.6 Sorrento Therapeutics Competitive Strengths & Weaknesses
6.11 Mustang Bio
6.11.1 Mustang Bio Details
6.11.2 Mustang Bio Major Business
6.11.3 Mustang Bio Drug based on CAR T-Cell Product and Services
6.11.4 Mustang Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.11.5 Mustang Bio Recent Developments/Updates
6.11.6 Mustang Bio Competitive Strengths & Weaknesses
6.12 Bluebird Bio
6.12.1 Bluebird Bio Details
6.12.2 Bluebird Bio Major Business
6.12.3 Bluebird Bio Drug based on CAR T-Cell Product and Services
6.12.4 Bluebird Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.12.5 Bluebird Bio Recent Developments/Updates
6.12.6 Bluebird Bio Competitive Strengths & Weaknesses
6.13 Cellectis
6.13.1 Cellectis Details
6.13.2 Cellectis Major Business
6.13.3 Cellectis Drug based on CAR T-Cell Product and Services
6.13.4 Cellectis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.13.5 Cellectis Recent Developments/Updates
6.13.6 Cellectis Competitive Strengths & Weaknesses
6.14 Allogene Therapeutics
6.14.1 Allogene Therapeutics Details
6.14.2 Allogene Therapeutics Major Business
6.14.3 Allogene Therapeutics Drug based on CAR T-Cell Product and Services
6.14.4 Allogene Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.14.5 Allogene Therapeutics Recent Developments/Updates
6.14.6 Allogene Therapeutics Competitive Strengths & Weaknesses
6.15 Celyad
6.15.1 Celyad Details
6.15.2 Celyad Major Business
6.15.3 Celyad Drug based on CAR T-Cell Product and Services
6.15.4 Celyad Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022)
6.15.5 Celyad Recent Developments/Updates
6.15.6 Celyad Competitive Strengths & Weaknesses
7 RAW MATERIAL AND INDUSTRY CHAIN
7.1 Raw Material of Drug based on CAR T-Cell and Key Manufacturers
7.2 Drug based on CAR T-Cell Manufacturing Costs
7.3 Drug based on CAR T-Cell Production Process
7.4 Drug based on CAR T-Cell Industrial Chain
8 DISTRIBUTION CHANNEL ANALYSIS
8.1 Distribution Channel Breakdown for Drug based on CAR T-Cell Shipments (%): 2017-2028
8.1.1 Direct Channel
8.1.2 Indirect Channel
8.2 Drug based on CAR T-Cell Typical Distributors
8.3 Drug based on CAR T-Cell Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Drug based on CAR T-Cell Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Drug based on CAR T-Cell Market Size by Region (2017-2022) & (USD Million)
Table 3. World Drug based on CAR T-Cell Market Size by Region (2023-2028) & (USD Million)
Table 4. World Drug based on CAR T-Cell Market Size Market Share by Region (2017-2022)
Table 5. World Drug based on CAR T-Cell Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Drug based on CAR T-Cell Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Drug based on CAR T-Cell Players in 2021
Table 9. World Drug based on CAR T-Cell Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Drug based on CAR T-Cell Company Evaluation Quadrant
Table 11. Head Office of Key Drug based on CAR T-Cell Player
Table 12. Drug based on CAR T-Cell Market: Company Product Type Footprint
Table 13. Drug based on CAR T-Cell Market: Company Product Application Footprint
Table 14. Drug based on CAR T-Cell Mergers & Acquisitions Activity
Table 15. United States VS China Drug based on CAR T-Cell Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Drug based on CAR T-Cell in United States, Headquarters (States, Country)
Table 17. United States Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Drug based on CAR T-Cell Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Drug based on CAR T-Cell in China, Company Headquarters (Province, Country)
Table 20. China Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Drug based on CAR T-Cell Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Drug based on CAR T-Cell in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Drug based on CAR T-Cell Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Drug based on CAR T-Cell Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Drug based on CAR T-Cell Revenue by Type (2017-2022) & (USD Million)
Table 27. World Drug based on CAR T-Cell Revenue by Type (2023-2028) & (USD Million)
Table 28. World Drug based on CAR T-Cell Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Drug based on CAR T-Cell Revenue by Application (2017-2022) & (USD Million)
Table 30. World Drug based on CAR T-Cell Revenue by Application (2023-2028) & (USD Million)
Table 31. Novartis Basic Information, Manufacturing Base and Competitors
Table 32. Novartis Major Business
Table 33. Novartis Drug based on CAR T-Cell Product and Services
Table 34. Novartis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Novartis Recent Developments/Updates
Table 36. Novartis Competitive Strengths & Weaknesses
Table 37. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 38. Gilead Sciences Major Business
Table 39. Gilead Sciences Drug based on CAR T-Cell Product and Services
Table 40. Gilead Sciences Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Gilead Sciences Recent Developments/Updates
Table 42. Gilead Sciences Competitive Strengths & Weaknesses
Table 43. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 44. Bristol-Myers Squibb Major Business
Table 45. Bristol-Myers Squibb Drug based on CAR T-Cell Product and Services
Table 46. Bristol-Myers Squibb Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Bristol-Myers Squibb Recent Developments/Updates
Table 48. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 49. J & J Basic Information, Manufacturing Base and Competitors
Table 50. J & J Major Business
Table 51. J & J Drug based on CAR T-Cell Product and Services
Table 52. J & J Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. J & J Recent Developments/Updates
Table 54. J & J Competitive Strengths & Weaknesses
Table 55. JW Therapeutics Basic Information, Manufacturing Base and Competitors
Table 56. JW Therapeutics Major Business
Table 57. JW Therapeutics Drug based on CAR T-Cell Product and Services
Table 58. JW Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. JW Therapeutics Recent Developments/Updates
Table 60. JW Therapeutics Competitive Strengths & Weaknesses
Table 61. FOSUNKite Basic Information, Manufacturing Base and Competitors
Table 62. FOSUNKite Major Business
Table 63. FOSUNKite Drug based on CAR T-Cell Product and Services
Table 64. FOSUNKite Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. FOSUNKite Recent Developments/Updates
Table 66. FOSUNKite Competitive Strengths & Weaknesses
Table 67. CARsgen Therapeutics (Pipeline) Basic Information, Manufacturing Base and Competitors
Table 68. CARsgen Therapeutics (Pipeline) Major Business
Table 69. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product and Services
Table 70. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. CARsgen Therapeutics (Pipeline) Recent Developments/Updates
Table 72. CARsgen Therapeutics (Pipeline) Competitive Strengths & Weaknesses
Table 73. CARsgen Therapeutics Basic Information, Manufacturing Base and Competitors
Table 74. CARsgen Therapeutics Major Business
Table 75. CARsgen Therapeutics Drug based on CAR T-Cell Product and Services
Table 76. CARsgen Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. CARsgen Therapeutics Recent Developments/Updates
Table 78. CARsgen Therapeutics Competitive Strengths & Weaknesses
Table 79. Autolus Therapeutics Basic Information, Manufacturing Base and Competitors
Table 80. Autolus Therapeutics Major Business
Table 81. Autolus Therapeutics Drug based on CAR T-Cell Product and Services
Table 82. Autolus Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Autolus Therapeutics Recent Developments/Updates
Table 84. Autolus Therapeutics Competitive Strengths & Weaknesses
Table 85. Sorrento Therapeutics Basic Information, Manufacturing Base and Competitors
Table 86. Sorrento Therapeutics Major Business
Table 87. Sorrento Therapeutics Drug based on CAR T-Cell Product and Services
Table 88. Sorrento Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. Sorrento Therapeutics Recent Developments/Updates
Table 90. Sorrento Therapeutics Competitive Strengths & Weaknesses
Table 91. Mustang Bio Basic Information, Manufacturing Base and Competitors
Table 92. Mustang Bio Major Business
Table 93. Mustang Bio Drug based on CAR T-Cell Product and Services
Table 94. Mustang Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 95. Mustang Bio Recent Developments/Updates
Table 96. Mustang Bio Competitive Strengths & Weaknesses
Table 97. Bluebird Bio Basic Information, Manufacturing Base and Competitors
Table 98. Bluebird Bio Major Business
Table 99. Bluebird Bio Drug based on CAR T-Cell Product and Services
Table 100. Bluebird Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 101. Bluebird Bio Recent Developments/Updates
Table 102. Bluebird Bio Competitive Strengths & Weaknesses
Table 103. Cellectis Basic Information, Manufacturing Base and Competitors
Table 104. Cellectis Major Business
Table 105. Cellectis Drug based on CAR T-Cell Product and Services
Table 106. Cellectis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 107. Cellectis Recent Developments/Updates
Table 108. Cellectis Competitive Strengths & Weaknesses
Table 109. Allogene Therapeutics Basic Information, Manufacturing Base and Competitors
Table 110. Allogene Therapeutics Major Business
Table 111. Allogene Therapeutics Drug based on CAR T-Cell Product and Services
Table 112. Allogene Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 113. Allogene Therapeutics Recent Developments/Updates
Table 114. Celyad Basic Information, Manufacturing Base and Competitors
Table 115. Celyad Major Business
Table 116. Celyad Drug based on CAR T-Cell Product and Services
Table 117. Celyad Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 118. Drug based on CAR T-Cell Raw Material
Table 119. Key Manufacturers of Drug based on CAR T-Cell Raw Materials
Table 120. Drug based on CAR T-Cell Typical Distributors
Table 121. Drug based on CAR T-Cell Typical Customers
Table 1. World Drug based on CAR T-Cell Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Drug based on CAR T-Cell Market Size by Region (2017-2022) & (USD Million)
Table 3. World Drug based on CAR T-Cell Market Size by Region (2023-2028) & (USD Million)
Table 4. World Drug based on CAR T-Cell Market Size Market Share by Region (2017-2022)
Table 5. World Drug based on CAR T-Cell Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Drug based on CAR T-Cell Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Drug based on CAR T-Cell Players in 2021
Table 9. World Drug based on CAR T-Cell Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Drug based on CAR T-Cell Company Evaluation Quadrant
Table 11. Head Office of Key Drug based on CAR T-Cell Player
Table 12. Drug based on CAR T-Cell Market: Company Product Type Footprint
Table 13. Drug based on CAR T-Cell Market: Company Product Application Footprint
Table 14. Drug based on CAR T-Cell Mergers & Acquisitions Activity
Table 15. United States VS China Drug based on CAR T-Cell Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Drug based on CAR T-Cell in United States, Headquarters (States, Country)
Table 17. United States Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Drug based on CAR T-Cell Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Drug based on CAR T-Cell in China, Company Headquarters (Province, Country)
Table 20. China Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Drug based on CAR T-Cell Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Drug based on CAR T-Cell in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Drug based on CAR T-Cell Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Drug based on CAR T-Cell Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Drug based on CAR T-Cell Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Drug based on CAR T-Cell Revenue by Type (2017-2022) & (USD Million)
Table 27. World Drug based on CAR T-Cell Revenue by Type (2023-2028) & (USD Million)
Table 28. World Drug based on CAR T-Cell Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Drug based on CAR T-Cell Revenue by Application (2017-2022) & (USD Million)
Table 30. World Drug based on CAR T-Cell Revenue by Application (2023-2028) & (USD Million)
Table 31. Novartis Basic Information, Manufacturing Base and Competitors
Table 32. Novartis Major Business
Table 33. Novartis Drug based on CAR T-Cell Product and Services
Table 34. Novartis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Novartis Recent Developments/Updates
Table 36. Novartis Competitive Strengths & Weaknesses
Table 37. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 38. Gilead Sciences Major Business
Table 39. Gilead Sciences Drug based on CAR T-Cell Product and Services
Table 40. Gilead Sciences Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Gilead Sciences Recent Developments/Updates
Table 42. Gilead Sciences Competitive Strengths & Weaknesses
Table 43. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 44. Bristol-Myers Squibb Major Business
Table 45. Bristol-Myers Squibb Drug based on CAR T-Cell Product and Services
Table 46. Bristol-Myers Squibb Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. Bristol-Myers Squibb Recent Developments/Updates
Table 48. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 49. J & J Basic Information, Manufacturing Base and Competitors
Table 50. J & J Major Business
Table 51. J & J Drug based on CAR T-Cell Product and Services
Table 52. J & J Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. J & J Recent Developments/Updates
Table 54. J & J Competitive Strengths & Weaknesses
Table 55. JW Therapeutics Basic Information, Manufacturing Base and Competitors
Table 56. JW Therapeutics Major Business
Table 57. JW Therapeutics Drug based on CAR T-Cell Product and Services
Table 58. JW Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. JW Therapeutics Recent Developments/Updates
Table 60. JW Therapeutics Competitive Strengths & Weaknesses
Table 61. FOSUNKite Basic Information, Manufacturing Base and Competitors
Table 62. FOSUNKite Major Business
Table 63. FOSUNKite Drug based on CAR T-Cell Product and Services
Table 64. FOSUNKite Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. FOSUNKite Recent Developments/Updates
Table 66. FOSUNKite Competitive Strengths & Weaknesses
Table 67. CARsgen Therapeutics (Pipeline) Basic Information, Manufacturing Base and Competitors
Table 68. CARsgen Therapeutics (Pipeline) Major Business
Table 69. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product and Services
Table 70. CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. CARsgen Therapeutics (Pipeline) Recent Developments/Updates
Table 72. CARsgen Therapeutics (Pipeline) Competitive Strengths & Weaknesses
Table 73. CARsgen Therapeutics Basic Information, Manufacturing Base and Competitors
Table 74. CARsgen Therapeutics Major Business
Table 75. CARsgen Therapeutics Drug based on CAR T-Cell Product and Services
Table 76. CARsgen Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. CARsgen Therapeutics Recent Developments/Updates
Table 78. CARsgen Therapeutics Competitive Strengths & Weaknesses
Table 79. Autolus Therapeutics Basic Information, Manufacturing Base and Competitors
Table 80. Autolus Therapeutics Major Business
Table 81. Autolus Therapeutics Drug based on CAR T-Cell Product and Services
Table 82. Autolus Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Autolus Therapeutics Recent Developments/Updates
Table 84. Autolus Therapeutics Competitive Strengths & Weaknesses
Table 85. Sorrento Therapeutics Basic Information, Manufacturing Base and Competitors
Table 86. Sorrento Therapeutics Major Business
Table 87. Sorrento Therapeutics Drug based on CAR T-Cell Product and Services
Table 88. Sorrento Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. Sorrento Therapeutics Recent Developments/Updates
Table 90. Sorrento Therapeutics Competitive Strengths & Weaknesses
Table 91. Mustang Bio Basic Information, Manufacturing Base and Competitors
Table 92. Mustang Bio Major Business
Table 93. Mustang Bio Drug based on CAR T-Cell Product and Services
Table 94. Mustang Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 95. Mustang Bio Recent Developments/Updates
Table 96. Mustang Bio Competitive Strengths & Weaknesses
Table 97. Bluebird Bio Basic Information, Manufacturing Base and Competitors
Table 98. Bluebird Bio Major Business
Table 99. Bluebird Bio Drug based on CAR T-Cell Product and Services
Table 100. Bluebird Bio Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 101. Bluebird Bio Recent Developments/Updates
Table 102. Bluebird Bio Competitive Strengths & Weaknesses
Table 103. Cellectis Basic Information, Manufacturing Base and Competitors
Table 104. Cellectis Major Business
Table 105. Cellectis Drug based on CAR T-Cell Product and Services
Table 106. Cellectis Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 107. Cellectis Recent Developments/Updates
Table 108. Cellectis Competitive Strengths & Weaknesses
Table 109. Allogene Therapeutics Basic Information, Manufacturing Base and Competitors
Table 110. Allogene Therapeutics Major Business
Table 111. Allogene Therapeutics Drug based on CAR T-Cell Product and Services
Table 112. Allogene Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 113. Allogene Therapeutics Recent Developments/Updates
Table 114. Celyad Basic Information, Manufacturing Base and Competitors
Table 115. Celyad Major Business
Table 116. Celyad Drug based on CAR T-Cell Product and Services
Table 117. Celyad Drug based on CAR T-Cell Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 118. Drug based on CAR T-Cell Raw Material
Table 119. Key Manufacturers of Drug based on CAR T-Cell Raw Materials
Table 120. Drug based on CAR T-Cell Typical Distributors
Table 121. Drug based on CAR T-Cell Typical Customers
LIST OF FIGURES
Figure 1. Drug based on CAR T-Cell Picture
Figure 2. World Drug based on CAR T-Cell Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Drug based on CAR T-Cell Total Market Size (2017-2028) & (USD Million)
Figure 4. World Drug based on CAR T-Cell Market Size Market Share by Region (2017-2028)
Figure 5. United States Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 6. China Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 7. Europe Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 8. Japan Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 11. India Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 12. Drug based on CAR T-Cell Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Drug based on CAR T-Cell by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Drug based on CAR T-Cell Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Drug based on CAR T-Cell Markets in 2021
Figure 17. United States VS China: Drug based on CAR T-Cell Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Drug based on CAR T-Cell Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Drug based on CAR T-Cell Market Size Market Share by Type in 2021
Figure 20. CD19-targeted
Figure 21. BCMA-targeted
Figure 22. World Drug based on CAR T-Cell Market Size Market Share by Type (2017-2028)
Figure 23. World Drug based on CAR T-Cell Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 24. World Drug based on CAR T-Cell Market Size Market Share by Application in 2021
Figure 25. Lymphoma
Figure 26. Multiple Myeloma
Figure 27. World Drug based on CAR T-Cell Market Size Market Share by Application (2017-2028)
Figure 28. Manufacturing Cost Structure Analysis of Drug based on CAR T-Cell in 2021
Figure 29. Manufacturing Process Analysis of Drug based on CAR T-Cell
Figure 30. Drug based on CAR T-Cell Industrial Chain
Figure 31. Distribution Channel Breakdown for Drug based on CAR T-Cell Shipments (%): 2017-2028
Figure 32. Direct Channel Pros & Cons
Figure 33. Indirect Channel Pros & Cons
Figure 34. Methodology
Figure 35. Research Process and Data Source
Figure 1. Drug based on CAR T-Cell Picture
Figure 2. World Drug based on CAR T-Cell Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Drug based on CAR T-Cell Total Market Size (2017-2028) & (USD Million)
Figure 4. World Drug based on CAR T-Cell Market Size Market Share by Region (2017-2028)
Figure 5. United States Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 6. China Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 7. Europe Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 8. Japan Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 11. India Drug based on CAR T-Cell Market Size (2017-2028) & (USD Million)
Figure 12. Drug based on CAR T-Cell Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Drug based on CAR T-Cell by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Drug based on CAR T-Cell Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Drug based on CAR T-Cell Markets in 2021
Figure 17. United States VS China: Drug based on CAR T-Cell Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Drug based on CAR T-Cell Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Drug based on CAR T-Cell Market Size Market Share by Type in 2021
Figure 20. CD19-targeted
Figure 21. BCMA-targeted
Figure 22. World Drug based on CAR T-Cell Market Size Market Share by Type (2017-2028)
Figure 23. World Drug based on CAR T-Cell Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 24. World Drug based on CAR T-Cell Market Size Market Share by Application in 2021
Figure 25. Lymphoma
Figure 26. Multiple Myeloma
Figure 27. World Drug based on CAR T-Cell Market Size Market Share by Application (2017-2028)
Figure 28. Manufacturing Cost Structure Analysis of Drug based on CAR T-Cell in 2021
Figure 29. Manufacturing Process Analysis of Drug based on CAR T-Cell
Figure 30. Drug based on CAR T-Cell Industrial Chain
Figure 31. Distribution Channel Breakdown for Drug based on CAR T-Cell Shipments (%): 2017-2028
Figure 32. Direct Channel Pros & Cons
Figure 33. Indirect Channel Pros & Cons
Figure 34. Methodology
Figure 35. Research Process and Data Source
